Jazz Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. The company's product portfolio includes three marketed products, namely, Xyrem, Luvox CR and Antizol.

Report Highlights
The company's product portfolio include Xyrem, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Luvox CR, for the treatment of obsessive compulsive disorder social anxiety disorder; and Antizol, for the treatment of ethylene glycol and methanol poisoning.

Its product pipeline comprises JZP-6, the company's lead candidate undergoing Phase III trials for the treatment of fibromyalgia syndrome and Phase II programs in recurrent acute repetitive seizures (JZP-8), epilepsy bipolar disorder (JZP-4) and restless legs syndrome (JZP-7).

Jazz Pharmaceuticals' major contributor to the total sales growth out to 2010 will be the revenues from the product sales of Luvox CR. Luvox CR product revenues are expected to increase from $42 million in 2008 (year of launch) to $166 million in 2010.
[Studien Infos ausblenden]

Overview 1
Catalyst 1
Summary 1
Company Structure 7
Company Overview and Key Facts 7
Business Description 8
History 9
Company Financials 11
P&L 11
Balance Sheet 14
Cash Flow 14
Business Segment Performance 15
Geographic Segment Performance 17
Products & Services 18
Marketed Products 18
Pipeline Products 19
Historical Product Sales 21
AC Forecast Product Sales 22
Competitors and Strategic Business Relationships 24
Top Competitors 24
Key Suppliers 25
Key Clients 25
Shareholding Structure 26
Strategy 27
Corporate Strategy 27
SWOT Analysis 29
Overview 29
Strengths 30
Weaknesses 31
Opportunities 32
Threats 33
Value Chain Analysis 34
Overview 34
Discovery and Product Development 35
Sales 35
Scorecard 36
Overview 36
Scorecard Analysis 37
Key Employees 38
List of Key Employees 38
Key Employee Biographies 39
Financial and Operational Overview 47
Financial and Operational Overview 47
Appendix 49
Ask the analyst 49
Datamonitor consulting 49
Disclaimer 49
[Inhaltsverzeichnis ausblenden]

Table 1: Jazz Pharmaceuticals - Key Facts 7
Table 2: Jazz Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11
Table 3: Jazz Pharmaceuticals - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 13
Table 4: Jazz Pharmaceuticals - Balance Sheet, 2002-2006 ($ Mn) 14
Table 5: Jazz Pharmaceuticals - Balance Sheet, 2002-2006 ($ Mn) 14
Table 6: Jazz Pharmaceuticals - Revenue Breakdown, 2002-2006 ($ Mn) 15
Table 7: Jazz Pharmaceuticals - Geographic Breakdown, 2002-2006 ($ Mn) 17
Table 8: Jazz Pharmaceuticals – Marketed Products 18
Table 9: Jazz Pharmaceuticals – In-house Pipeline Products 19
Table 10: Jazz Pharmaceuticals – Collaboration Pipeline Products 20
Table 11: Jazz Pharmaceuticals – Historical Product Sales, 2002-2006 ($ Mn) 21
Table 12: Jazz Pharmaceuticals – Forecast Sales, 2006-2010 ($ Mn) 22
Table 13: Jazz Pharmaceuticals – Top Competitors 24
Table 14: Jazz Pharmaceuticals – Key Suppliers 25
Table 15: Jazz Pharmaceuticals – Key Clients 25
Table 16: Jazz Pharmaceuticals - Key Shareholders 26
Table 17: Jazz Pharmaceuticals - SWOT Analysis Summary 29
Table 18: Jazz Pharmaceuticals – Value Chain Analysis 34
Table 19: Jazz Pharmaceuticals - Scorecard 36
Table 20: Jazz Pharmaceuticals - Key Employees 38
Table 21: Jazz Pharmaceuticals - Financial and Operational Overview 47
Figure 1: Jazz Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
Figure 2: Jazz Pharmaceuticals – Key Strategic Revenues, 2002-2006 ($ Mn) 16
Figure 3: Jazz Pharmaceuticals – Key Strategic Revenues, 2006-2010 ($ Mn) 23
[Tabellenverzeichnis ausblenden]